Valproic Acid

"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.

Descriptor ID	D014635
MeSH Number(s)	D02.241.081.944.509.900 D10.251.400.895.593.900
Concept/Terms	Valproic Acid Valproic Acid Propylisopropylacetic Acid 2-Propylpentanoic Acid 2 Propylpentanoic Acid Divalproex Depakene Depakene Depakine Convulsofin Convulsofin Depakote Depakote Vupral Vupral Divalproex Sodium Divalproex Sodium Semisodium Valproate Valproic Acid, Sodium Salt (2:1) Ergenyl Ergenyl Magnesium Valproate Magnesium Valproate Valproate Valproate Valproate Sodium Valproate Sodium Sodium Valproate Valproate, Sodium Calcium Valproate Calcium Valproate Valproate, Calcium Valproate Calcium Dipropyl Acetate Dipropyl Acetate

Below are MeSH descriptors whose meaning is more general than "Valproic Acid".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Valerates [D02.241.081.944]
Pentanoic Acids [D02.241.081.944.509]
Valproic Acid [D02.241.081.944.509.900]
Lipids [D10]
Fatty Acids [D10.251]
Fatty Acids, Volatile [D10.251.400]
Valerates [D10.251.400.895]
Pentanoic Acids [D10.251.400.895.593]
Valproic Acid [D10.251.400.895.593.900]

Below are MeSH descriptors whose meaning is related to "Valproic Acid".

Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.

Bar chart showing 44 publications over 22 distinct years, with a maximum of 5 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	2	0	2
1995	1	1	2
1996	1	1	2
1997	1	0	1
1999	0	1	1
2000	1	1	2
2001	1	2	3
2002	1	0	1
2003	2	0	2
2004	0	1	1
2005	1	1	2
2007	1	0	1
2009	2	0	2
2010	2	0	2
2011	2	0	2
2012	1	1	2
2013	0	2	2
2014	0	3	3
2017	1	0	1
2019	2	1	3
2020	2	0	2
2021	1	4	5

Below are the most recent publications written about "Valproic Acid" by people in Profiles.

Wabl R, Terman SW, Kwok M, Elm J, Chamberlain J, Silbergleit R, Hill CE. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021 08 17; 97(7):e720-e727.

View in: PubMed
Sathe AG, Brundage RC, Ivaturi V, Cloyd JC, Chamberlain JM, Elm JJ, Silbergleit R, Kapur J, Coles LD. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021 07; 14(4):1444-1451.

View in: PubMed
Wang D, Champion-Lyons E, Neyens R, Bohm N, Caddell B, Babic N. The Effect of Sample Handling on Free Valproic Acid Levels. J Appl Lab Med. 2021 04 29; 6(3):645-653.

View in: PubMed
Urrea-Mendoza E, Okafor K, Ravindran S, Absher J, Chaubal V, Revilla FJ. Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis. Tremor Other Hyperkinet Mov (N Y). 2021 02 10; 11:7.

View in: PubMed
Sathe AG, Mishra U, Ivaturi V, Brundage RC, Cloyd JC, Elm JJ, Chamberlain JM, Silbergleit R, Kapur J, Lowenstein DH, Shinnar S, Cock HR, Fountain NB, Babcock L, Coles LD. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. J Clin Pharmacol. 2021 06; 61(6):763-768.

View in: PubMed
Sathe AG, Elm JJ, Cloyd JC, Chamberlain JM, Silbergleit R, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DH, Conwit RA, Bleck TP, Coles LD. The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.

View in: PubMed
Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.

View in: PubMed
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.

View in: PubMed
Cock HR, Coles LD, Elm J, Silbergleit R, Chamberlain JM, Cloyd JC, Fountain N, Shinnar S, Lowenstein D, Conwit R, Bleck TP, Kapur J. Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.

View in: PubMed
Drisaldi A, Weeda E, Neyens R, Orvin N, Bonilha L, Campbell Z, Bohm N. Accuracy of Valproic Acid Concentration Correction Based on Serum Albumin. Neurocrit Care. 2019 04; 30(2):301-306.

View in: PubMed

People

Explore

Similar Concepts

Top Journals